Skip to content
MarketScale
‹ Back to IndustriesSciences

Choosing the Right Tree: Understanding Your Desired Space

When faced with the task of replacing a removed tree in your yard, careful consideration of the available space and desired functionality is essential. In this enlightening conversation, Wes Rivers, VP of Operations at TreeNewal, shares valuable insights on choosing the right tree species based on its intended purpose and compatibility with the surrounding…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Wes Rivers · Economic BenefitsProperty ValueSpace CompatibilityTree Functionality
Share

Key takeaways

01

When faced with the task of replacing a removed tree in your yard, careful consideration of the available space and desired functionality is essential.

02

In this enlightening conversation, Wes Rivers, VP of Operations at TreeNewal, shares valuable insights on choosing the right tree species based on its intended purpose and compatibility with the surrounding…

When faced with the task of replacing a removed tree in your yard, careful consideration of the available space and desired functionality is essential. In this enlightening conversation, Wes Rivers, VP of Operations at TreeNewal, shares valuable insights on choosing the right tree species based on its intended purpose and compatibility with the surrounding environment. Making an informed decision not only enhances the aesthetics but also increases the economic benefits and overall value of your property.

Teasing the Core Question:

How can homeowners ensure they are choosing the right to replace a removed one, considering the specific functions they want the tree to fulfill and the characteristics of the space?

In this educational soundbite, Wes Rivers, VP of Operations at TreeNewal, provides expert guidance on selecting suitable trees that match the desired functionalities and seamlessly fit into the available space.

Key Points Discussed:

  • Identifying the functions you want the new tree to serve, such as screening, shade, aesthetics, or soil retention.
  • Considering the compatibility of the tree species with the designated space, avoiding potential conflicts with foundations, sun exposure, or moisture levels.
  • Recognizing the various economic benefits associated with tree replacements, such as increased property value, shading, and evaporative cooling.

Guest Bio:

Wes Rivers, Vice President of Operations at TreeNewal, brings his extensive knowledge and experience in tree selection and property enhancement. With his insightful advice, Wes helps homeowners make informed decisions to choose the perfect tree replacements that provide both functionality and value.

About the author

WR

Wes Rivers is a dedicated and accomplished professional in the field of arboriculture and tree care, with a strong passion for preserving and enhancing the natural environment. As an alumnus of SFA University, where he earned his degree in Forestry and Environmental Science, Wesley has cultivated a deep understanding of trees and their ecological significance.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

WR
Wes Rivers

Wes Rivers is a dedicated and accomplished professional in the field of arboriculture and tree care, with a strong passion for preserving and enhancing the natural environment. As an alumnus of SFA University, where he earned his degree in Forestry and Environmental Science, Wesley has cultivated a deep understanding of trees and their ecological significance.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512